<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013970</url>
  </required_header>
  <id_info>
    <org_study_id>S62757</org_study_id>
    <nct_id>NCT05013970</nct_id>
  </id_info>
  <brief_title>Pilot Study of Transcatheter Arterial Embolization as a Treatment for Knee Pain in Patients With Mild to Moderate Osteoarthritis</brief_title>
  <official_title>Pilot Study of Transcatheter Arterial Embolization as a Treatment for Knee Pain in Patients With Mild to Moderate Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disabling symptoms of osteoarthritis are seen in approximatively 10% of people over 55 years&#xD;
      old. Many patients suffer from persistent pain symptoms from moderate osteoarthritis despite&#xD;
      optimal medical treatment. For these patients, several minimally-invasive surgical treatments&#xD;
      have been proposed, including arthroscopic lavage and debridement; however, none of these&#xD;
      treatments have been proven effective compared to sham treatment.&#xD;
&#xD;
      Recently, catheter-directed embolotherapy of the geniculate arteries has been propagated as a&#xD;
      real alternative to medical management in patients with mild to moderate knee osteoarthritis&#xD;
      unresponsive to conservative medical management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disabling symptoms of osteoarthritis are seen in approximatively 10% of people over 55 years&#xD;
      old. Traditionally, treatment of symptomatic knee osteoarthritis is based on administration&#xD;
      of pain relievers, including nonsteroidal anti-inflammatory drugs, in case of mild to&#xD;
      moderate symptoms; major joint replacement surgery (total joint arthroplasty) is performed in&#xD;
      cases of severe and end-stage osteoarthritis.&#xD;
&#xD;
      However, many patients suffer from persistent pain symptoms from moderate osteoarthritis&#xD;
      despite optimal medical treatment. For these patients, several minimally-invasive surgical&#xD;
      treatments have been proposed, including arthroscopic lavage and debridement; however, none&#xD;
      of these treatments have been proven effective compared to sham treatment.&#xD;
&#xD;
      Recently, catheter-directed embolotherapy of the geniculate arteries has been propagated as a&#xD;
      real alternative to medical management in patients with mild to moderate knee osteoarthritis&#xD;
      unresponsive to conservative medical management.&#xD;
&#xD;
      Transcatheter embolotherapy was performed using imipenem/cilastin sodium or 75 micron&#xD;
      calibrated Embozene microspheres and follow-up was performed by physical examination,&#xD;
      questionnaires (VAS-score and WOMAC-scores) and MR-imaging (WORMS-score). Results of these&#xD;
      trials confirmed that catheter-directed embolotherapy is a safe procedure without any major&#xD;
      adverse events. WOMAC pain scores dropped dramatically from 12.2 +/- 1.9 before the procedure&#xD;
      to 3.3 +/- 2.1 at 1 month after the procedure and to 1.7 +/- 2.2 at 4 months after the&#xD;
      procedure. Additionally, MR imaging at 2 years of follow-up could not demonstrate any&#xD;
      osteonecrosis or progression of degenerative changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with mild to moderate knee osteoarthritis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) for Knee Pain</measure>
    <time_frame>Within 30 days after catheter-directed embolization</time_frame>
    <description>To measure pain in patients with knee osteoarthritis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire</measure>
    <time_frame>Within 30 days after catheter-directed embolization</time_frame>
    <description>To evaluate symptoms and limitations in patients with knee osteoarthritis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI imaging</measure>
    <time_frame>At day 30 after catheter-directed embolization</time_frame>
    <description>To depict potential asymptomatic, but radiologically visible side-effects</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Knee osteoarthritis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with mild to moderate osteoarthritis who suffer from persistent knee pain treated with catheter-directed geniculate artery embolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical assessment</intervention_name>
    <description>Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire</description>
    <arm_group_label>Knee osteoarthritis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiographic imaging</intervention_name>
    <description>MRI of the knee</description>
    <arm_group_label>Knee osteoarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of knee pain&#xD;
&#xD;
          -  Kellgren-Lawrence (KL) grade 1-3 assessed by weight-bearing knee radiographs&#xD;
&#xD;
          -  Local tenderness around the knee&#xD;
&#xD;
          -  Clinical failure after 3 months or more of conservative therapies, including oral&#xD;
             nonsteroidal anti-inflammatory drugs and/or oral opioid agents and physical therapy,&#xD;
             stretching, muscle strengthening and/or intra-articular injection of hyaluronic acid&#xD;
&#xD;
          -  Persistent moderate to severe knee pain (VAS &gt; 50 mm) for more than 3 months&#xD;
&#xD;
          -  Patient is able to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous knee surgery&#xD;
&#xD;
          -  Local infection&#xD;
&#xD;
          -  BMI &gt; 40 kg/m2&#xD;
&#xD;
          -  Advanced atherosclerosis&#xD;
&#xD;
          -  Rheumatoid arthritis, malignancy, renal insufficiency, other conditions&#xD;
             contra-indicating femoropopliteal angiography&#xD;
&#xD;
          -  Usage of anticoagulants such as eliquis or coumarine (Asaflow allowed)&#xD;
&#xD;
          -  Allergy to iodinated contrast medium or any other allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Catheter-directed embolotherapy</keyword>
  <keyword>Poly-vinyl alcohol microspheres</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

